EGFR and neoplasm: Considering the improved benefits of NCT03513666A and the IMpower150 trial, a promising treatment was to combine ICIs with chemotherapy to improve the immunogenicity of tumor cells or anti-angiogenesis to promote more TIL infiltration into the tumor in EGFR-mutant NSCLC.